Angiotensin (1-7) receptor
Ohishi, M.; Rakugi, H.
Nihon Rinsho. Japanese Journal of Clinical Medicine 67(4): 681-685
2009
ISSN/ISBN: 0047-1852 PMID: 19348228 Document Number: 637491
Mas, which was protooncogene, first detected in vivo by tumorigenic properties originating from rearrangement of its 5'-flanking region was identified as a functional receptor for angiotensin (1-7) and provide a clear molecular basis for the physiological actions of this biologically active peptide. Angiotensin (1-7) is mainly produced from angiotensin II by angiotensin converting enzyme 2, homologue of angiotensin converting enzyme. Many investigations suggested angiotensin (1-7) via Mas receptor might play protective effects on hypertensive complications, such as renal dysfunction and cardiovascular diseases, competed with angiotensin II and its type 1 receptor.
Document emailed within 1 workday
Related Documents
De Paz, S.; Martín, A.B.; Iglesias, A.; Domínguez, A.R. 1999: Angioedema-urticaria caused by angiotensin-converting enzyme inhibitors and angiotensin Ii receptor antagonists Medicina Clinica 113(19): 759Jover, B.; Mimran, A. 1994: Angiotensin II receptor antagonists versus angiotensin converting enzyme inhibitors: effects on renal function Journal of Hypertension. Supplement: Official Journal of the International Society of Hypertension 12(9): S3-S9
Wong, P.C.; Timmermans, P.B. 1991: Nonpeptide angiotensin II receptor antagonists: insurmountable angiotensin II antagonism of EXP3892 is reversed by the surmountable antagonist DuP 753 Journal of Pharmacology and Experimental Therapeutics 258(1): 49-57
Krzesinski, J.M.; Montrieux, C.; Scheen, A.J. 2006: Angiotensin converting enzyme inhibitors or angiotensin Ii receptor blocker in cardiovascular and renal pathology in 2006: what does EBM teach us? Revue Medicale de Liege 61(5-6): 414-422
Iimura, O.; Kusano, E.; Tanba, K.; Yanagiba, S.; Amemiya, M.; Ando, Y.; Honma, S.; Muto, S.; Asano, Y. 2003: Additive antiproteinuric effect of angiotensin Ii receptor antagonist and angiotensin-converting enzyme inhibitor in patients with chronic glomerulonephritis Nihon Jinzo Gakkai Shi 45(5): 439-444
Anantharaman, R.; Bhansali, A.; Bhadada, S.K.; Kohli, H.S.; Dutta, P.; Walia, R.; Jayaprakash, P.; Upreti, V. 2010: Anti-albuminuric efficacy of a combination of angiotensin converting enzyme inhibitor and angiotensin receptor blocker in type 1 DM with nephropathy Indian Journal of Medical Research 132: 42-47
Surabenjawong, U.; Thunpiphat, N.; Chatsiricharoenkul, S.; Monsomboon, A. 2013: Prevalence of hyperkalemia in adult patients taking spironolactone and angiotensin converting enzyme inhibitors or angiotensin receptor blockers Journal of the Medical Association of Thailand 96(8): 905-910
Benetos, A.; Gautier, S.; Ricard, S.; Topouchian, J.; Asmar, R.; Poirier, O.; Larosa, E.; Guize, L.; Safar, M.; Soubrier, F.; Cambien, F. 1996: Influence of angiotensin-converting enzyme and angiotensin II type 1 receptor gene polymorphisms on aortic stiffness in normotensive and hypertensive patients Circulation 94(4): 698-703
Wang, L.; Cai, S.-r.; Zhang, C.-h.; He, Y.-l.; Zhan, W.-h.; Wu, H.; Peng, J.-j. 2008: Effects of angiotensin converting enzyme inhibitors and angiotensin Ii receptor blockers on angiogenesis of gastric cancer in a nude mouse model Zhonghua Wei Chang Wai Ke Za Zhi 11(6): 565-568
Wang, L.; Cai, S.-r.; Zhang, C.-h.; He, Y.-l.; Zhan, W.-h.; Wu, H.; Peng, J.-j. 2008: Effects of angiotensin-converting enzyme inhibitors and angiotensin Ii type 1 receptor blockers on lymphangiogenesis of gastric cancer in a nude mouse model Chinese Medical Journal 121(21): 2167-2171
Zhou, H.; Bian, Y-fei.; Li, M-lian.; Gao, F.; Xiao, C-shi. 2010: Effects of RNA interference targeting angiotensin 1 receptor and angiotensin-converting enzyme on blood pressure and myocardial remodeling in spontaneous hypertensive rats Zhonghua Xin Xue Guan Bing Za Zhi 38(1): 60-66
Antelava, N.A.; Gongadze, N.V.; Gogolauri, M.I.; Kezeli, T.D.; Pachkoriia, K.Z. 2007: Comparative characteristic of angiotensin-converting enzyme inhibitor--captopril and the angiotensin Ii receptor blokers--losartan action on the oxidative metabolism in experimental hyperlipidemia in rabbits Georgian Medical News 150: 57-60
Diskin, C.J.; Stokes, T.J.; Dansby, L.M.; Radcliff, L.; Carter, T.B. 2007: Will the addition of pentoxifylline reduce proteinuria in patients with diabetic glomerulosclerosis refractory to maximal doses of both an angiotensin-converting enzyme inhibitor and an angiotensin receptor blocker? Journal of Nephrology 20(4): 410-416
Spinale, F.G.; Holzgrefe, H.H.; Mukherjee, R.; Webb, M.L.; Hird, R.B.; Cavallo, M.J.; Powell, J.R.; Koster, W.H. 1997: Angiotensin-converting enzyme inhibition and angiotensin Ii subtype-1 receptor blockade during the progression of left ventricular dysfunction: differential effects on myocyte contractile processes Journal of Pharmacology and Experimental Therapeutics 283(3): 1082-1094
Zhang, R.-y.; Huang, Y.-l.; Sun, Y.-h. 2005: Effects of combination therapy with angiotensin I-converting enzyme inhibitor and angiotensin 1 receptor antagonist on ventricular remodeling and expression of endothelial nitric oxide synthase Zhonghua Yi Xue Za Zhi 85(15): 1053-1056
Vijan, S.G. 2009: Angiotensin-converting enzyme inhibitors (ACEIs), not angiotensin receptor blockers (ARBs), are preferred and effective mode of therapy in high cardiovascular risk patients Journal of the Indian Medical Association 107(3): 178-182
Renke, M.; Rutkowski, Pław.; Tylicki, L.; Zietkiewicz, M.; Larczyński, W.; Rutkowski, Bław. 2008: Clinical state of a patient with nephrotic proteinuria successfully treated with combined therapy with angiotensin II receptor antagonists and angiotensin II converting enzyme inhibitors and pentoxifylline Przeglad Lekarski 65(6): 312-314
Gong, J.-j.; Lu, Z.-q.; Cao, J.-l.; Xu, C.-s.; Wang, H.-j.; Jin, X.-q. 2012: Overexpression of angiotensin-converting enzyme 2 inhibits angiotensin Ii type 1 receptor expression and signal transducer and activator of transcription 3 phosphorylation in cultured smooth muscle cells Zhonghua Xin Xue Guan Bing Za Zhi 40(7): 607-613
Aoyama, N. 2007: Effect of combination therapy with angiotensin Ii type i receptor and aldosterone receptor blockers in heart failure Nihon Rinsho. Japanese Journal of Clinical Medicine 65(Suppl 5): 145-149
Philips, J.C.; Weekers, L.; Scheen, A.J. 2001: Clinical study of the month. The CALM study assessing the combination of an angiotensin-converting enzyme inhibitor and an angiotensin II receptor antagonist in the treatment of diabetic nephropathy Revue Medicale de Liege 56(2): 126-128